Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (82,181)	$ (29,500)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	566	2,404
Loss (gain) on disposal of equipment	(42)	281
Noncash interest expense	41	90
Stock-based compensation	4,029	4,016
Write-off of in-process R&D	50,618	0
Change in fair value of derivative liability	0	556
ROU asset amortization	1,058	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	534	(2,191)
Other long-term assets	0	(290)
Accounts payable	(194)	432
Accrued expenses	7,016	(1,551)
Operating lease liability	(1,111)	0
Settlement of derivative liability	0	(1,050)
Net cash used in operating activities	(19,666)	(26,803)
Cash flows from investing activities:
Purchases of property and equipment	(1,568)	(106)
Asset acquistion costs	(318)	0
Proceeds from sale of equipment	116	144
Net cash provided by (used in) investing activities	(1,770)	38
Cash flows from financing activities:
Proceeds from issuance of common stock	128,267	60,482
Issuance costs from issuance of common stock	(281)	(6,319)
Repayment of borrowings under loan	(9,375)	(5,625)
Net cash provided by financing activities	118,611	48,538
Net change in cash, cash equivalents and restricted cash	97,175	21,773
Cash, cash equivalents and restricted cash at beginning of year	47,339	25,566
Cash and cash equivalents at end of year	144,514	47,339
Supplemental disclosure of cash flow information
Cash paid for interest	370	854
Supplemental disclosure of financing activities
Conversion of preferred units	0	129,870
ROU asset acquired through operating leases	5,148	0
Issuance of common stock for acquisition of Trigr Therapeutics, Inc.	50,300	0
Fixed asset costs included in accrued expenses	$ 187	$ 0